Publications
227
Citations
14,097
Est. group size
—
Recurring co-author estimate
Active years
32
Publishing since 1993
Jeffrey A. Jones's work centers on clinical research in chronic lymphocytic leukemia (CLL) and related blood cancers, focusing on evaluating new drug therapies such as venetoclax, ibrutinib, duvelisib, and idelalisib. Much of this research involves multi-site clinical trials assessing the safety, effectiveness, and side effects of these targeted cancer treatments, including their use in patients whose disease has relapsed or resisted prior therapies.
Publication output peaked sharply around 2017-2018 and has substantially slowed since, with only about one publication per year on average over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Biomechanical Forces Can Promote SGK-1-dependent Expression of Pathologic Matrix Markers
JVS Vascular Science · 2024
- Data from Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
2023
- Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
American Journal of Hematology · 2018
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Blood · 2018
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Clinical Cancer Research · 2018
- Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
Blood · 2017
- Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
Blood · 2017
- Modified Venetoclax Dose Ramp-Up in Select High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) with Progression after B-Cell Receptor Pathway Inhibitors (BCRi)
Clinical Lymphoma Myeloma & Leukemia · 2017
- BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report
Journal of Medical Case Reports · 2017
- Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
Blood · 2017
- Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
British Journal of Haematology · 2017
- Ventricular arrhythmias and sudden death in patients taking ibrutinib
Blood · 2017
- Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Blood · 2017
- Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
Journal of Clinical Oncology · 2016
- Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.
Journal of Clinical Oncology · 2016
- Blood×34
- Journal of Clinical Oncology×12
- Blood Advances×4
- British Journal of Haematology×3
- Leukemia & lymphoma/Leukemia and lymphoma×3
- Jennifer A. Woyach
Medicine · The Ohio State University
- Mollie E. Moran
Medicine · The Ohio State University
- Kerry A. Rogers
Medicine · The Ohio State University
- Gerard Lozanski
Medicine · The Ohio State University
- Margaret S. Lucas
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile